Medical specialists from Israel tagged as investigators in clinical trials studying Primary Immunodeficiency Diseases

Total 1 results

Baruch Yerushalmi
Seen in:
- Be'er Sheba, Soroka University Medical Center
- Be'er Sheva, Soroka University Medical Centre
- Beer Sheba, Soroka University Medical Centre
- HaDarom, Be'er Sheva, Soroka Medical Center
- HaDarom, Beer-Sheva, Soroka Medical Center
Trials:
- NCT05509777 (Principal Investigator)
- NCT04779320 (Principal Investigator)
- NCT04779307 (Principal Investigator)
- NCT03148028 (Principal Investigator)
Conditions:

Clinical Trials on Primary Immunodeficiency Diseases

CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Primary Immunodeficiency (PID)

Poland, Germany, France, Romania, Spain, Sweden, Switzerland, United Kingdom
CSL Limited

Completed

Subcutaneous Ig NextGen 16% in PID Patients

Primary Immunodeficiency (PID)

Australia, New Zealand
CSL Behring

Completed

Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)

Primary Immune Deficiency

Japan
Ottawa Hospital Research Institute
Octapharma

Unknown

Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment

Primary Immunodeficiency Disease | Secondary Immunodeficiency

Canada
Shire

Completed

Retrospective, Observational Chart Review Study Conducted in Poland to Document the Management and Clinical Outcome of CUVITRU and HYQVIA in Pediatric Participants (< 18 Years) With Primary Immunodeficiency (PID) (IG-TATRY)

Primary Immunodeficiencies (PID)

Poland
Octapharma

Completed

Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps

Primary Immunodeficiency (PID)

France
Octapharma

Completed

CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL

Primary Immunodeficiency

United States, Canada
Assiut University

Completed

Minipooled-IVIG in Primary Immunodeficiency Disease

Primary Immunodeficiency

Egypt
CSL Behring

Completed

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

Primary Immunodeficiency

United States, Canada
IMMUNOe Research Centers

Completed

The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations

Primary Immunodeficiency

Medical specialists from Israel tagged as investigators in clinical trials studying Primary Immunodeficiency Diseases

Clinical Trials on Primary Immunodeficiency Diseases

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations